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1. Introduction 
Clinical needs to have a ready-to-use small-diameter vascular prostheses are very 
remarkable and cover different fields of surgery: plastic and reconstructive surgery 
(microvascular transfer of free flaps), heart surgery (treatment of ischemic heart diseases), 
vascular surgery (distal revascularization of lower limbs), neurosurgery (substitution of 
intracranial arteries), paediatric vascular surgery. In particular, there is a substantial need 
for tissue-engineered, living, autologous replacement materials with the potential for 
growth in paediatric applications and for substitute small diameter vessel that up to now are 
defined the “holy grail” of vascular biology. Completely bio-resorbable vascular prostheses 
with the capacity for induce regeneration and growth of a new vascular segment may 
overcome the limitations of contemporary artificial prostheses that are nonviable, artificial, 
or allogenic materials lacking the capacity of growth, repair, and remodelling. These 
intrinsic properties limit their long-term function, posing the substantial burden of graft 
failure and related re-operations, particularly on paediatric patient population. Moreover, 
these synthetic materials are not suitable for the reconstruction of the coronary, carotid, or 
femoral arteries as well as other small diameter vessels (< 6 mm). Autologous native vessels, 
i.e., the saphenous vein and mammary artery, are the most currently used material for 
small-diameter arterial replacement. Immune acceptance is a major advantage offered by 
this technique of “ready to use” conduits. However, the availability of suitable native 
replacements is limited when multiple conduits are required, especially in patients with 
diffuse vascular disease. The need for a prosthetic graft that performs as a small diameter 
conduit has led investigators to pursue many avenues in vascular biology (Figure 1). There 
are four main approaches currently being investigated, all of which satisfy an apparent 
prerequisite to biocompatibilty of a small-diameter graft—that no permanent synthetic 
materials are used. One approach is acellular, based on implanting decellularized tissues 
treated to enhance biocompatibility, strength, and cell adhesion/invasion leading to 
cellularization with host cells. The other three approaches involve implantation of constructs 
possessing some degree of cellularity. The most recent of these is based on the concept of 
self-assembly, wherein cells are cultured on tissue culture plastic in medium inducing high 
ECM synthesis. This leads to sheets of neotissue that are subsequently processed into 
multilayer tubular form. The other two approaches rely on a polymeric scaffold. One is  
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Fig. 1. The ideal micro-vascular prostheses should orchestrate the sequential regeneration of 
different vascular components: the intimal layer to avoid acute thrombosis, the smooth 
muscle vascular cell layer to respond to mechanical stimuli and finally the adventitial layer 
to obtain a long-term vascular patency. 
based on forming a tube of a synthetic biodegradable polymer and then seeding the cells 
(which would not survive the conditions of polymer synthesis), relying on active cell 
invasion or an applied force to achieve cellularity. The other is based on a tube of a 
biopolymer, typically a reconstituted type I collagen gel, formed with and compacted by 
tissue cells, where an appropriately applied mechanical constraint to the compaction yields 
circumferential alignment of fibrils and cells characteristic of the arterial media. It is this last 
feature that is most attractive about a biopolymer-based tissue-engineered artery. This 
follows from two axioms, (i) that native artery function, particularly mechanical function, 
depends on structure (particularly alignment of the smooth muscle cells and collagen fibers 
in the medial layer) as much as it depends on composition, and (ii) that the tissue-
engineered artery should serve as a functional remodelling template, so that while 
providing function during the remodelling, the artificial tissue also provides a template for 
the alignment of the remodelled tissue. To some extent, all these approaches rely on the 
ability of cells (transplanted or host) to adhere to and migrate within the construct, and to 
remodel its composition and/or structure. This last point is key, as remodelling confers 
biocompatibility, in principle, by virtue of complete resorption of the initial scaffold. Of 
course, the initial scaffold must be replaced by functional cell-derived ECM on the same 
time scale. Remodelling also determines the ultimate mechanical, transport, and biological 
properties. 
The aim of this chapter is to investigate all the materials commonly studied to create small 
diameter vascular prostheses. In particular, absorbable biomaterials are also reviewed in 
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depth, for better understanding of the properties of the biomaterials used until now in 
vascular engineering. A brief analysis of their two main features is necessary: surface 
properties (haemocompatibility/endothelialisation) and mechanical properties (tensile 
force/compliance). 
2. Material surface 
Thrombosis of vascular substitutes is the main mechanism of obliteration and subsequent 
failure of most vascular conduits. Various methods have been recorded to avoid this 
phenomenon, such as coatings with antithrombotic drugs, e.g., heparin, hirudin, aspirin, or 
tissue factor pathway inhibitor (Mooney DJ et al 1996; Kim BS et al 1998; Wake MC et al 
1996). There have been attempts to emulate the endothelial cellular surface which, coated 
with heparan sulphate proteoglycan, produces a negative surface charge which helps to 
prevent platelet adherence. Some prostheses are therefore coated internally with heparan 
sulphate, which is quickly degraded, and some materials with an electronegative surface 
have been created, with uncertain results (Guidoin R et al 1993).  
So far, many researchers have described seeding endothelial cells in conduits. A recent 
study reported a patency rate of 90% in 27 months for ePTFE prostheses used in coronary 
bypass, after additional incubation with endothelial cells which allowed them to adhere to 
the material (Laube HR et al 2000). The major limitation of this method is the need for cell 
cultures and withdrawal of tissue from the patient, and in any case it remains a two-step 
procedure. A tubular structure of ePTFE is also left in place, with the risk of later infection. 
Constructs composed entirely of cells (Tissue Engineered Blood Vessels: TEBV) have been 
devised to overcome these complications (Mooney DJ et al 1996; Kim BS et al 1998; Wake 
MC et al 1996). Although the method promises amazing results, it is time-consuming and 
very expensive.  
To avoid the cost of cell cultures, many researchers have tried to improve endothelial 
coverage of prostheses by coating them with endothelial-friendly compounds with good 
haemocompatibility. For example, e-PTFE prostheses have been coated with perlecan (Zenni 
GC et al 1993) and endothelial-specific adhesion proteins such as fibrin–gelatin (Kumar TR 
et al 2002) and hirudin (Salacinski H et al 2002). Fibronectin coating seems to be a successful 
method, apart from loss of lining at high flow rates. This is why a functional ligand for 
fibronectin was used, with covalent binding of short peptide sequences (Arg-Gly-Asp, RGD) 
to improve cell adhesion (Mooney DJ et al 1996; Kim BS et al 1998; Wake MC et al 1996).  
Instead of coating prostheses with the above substances, another possibility would be to use 
absorbable, already biocompatible biomaterials, to make entire prostheses (Kannan RY et al 
2005).  
In spite of all these experiments, endothelialisation in various types of vascular prostheses 
has been shown in animals but never satisfactorily in humans. The type of material is not 
the only essential point in favouring endothelialisation. In order to clarify this, we need to 
go back a little and recall the physiopathology of endothelialisation, which today takes place 
in three main ways:  
- Trans-anastomatic endothelialisation; 
- Transmural endothelialisation;  
- Endothelialisation due to 'fall-out' of circulating pluripotent cells.  
Therefore, trying to enhance endothelialisation means acting on each of these three 
modalites of cell growth.  
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Trans-anastomotic endothelialisation (TAE) appears to be very difficult in humans. Early 
studies on synthetic prostheses report that they cannot be longer than 0.5 cm, even after 
prolonged implantation. In spite of a long period of observation, internal endothelialisation 
has not been observed in humans, except in sites of anastomosis (Berger K et al 1972). 
Several factors have been observed to influence this, such as species, senescence, anatomic 
dimensions of the vessel, and prosthetic materials (Zilla P et al 2004), but even in animals 
TAE is limited (Zhang Z et al 2004).  
Study of endothelial cells, both human and canine, compared in vitro, suggest that human 
cells have a greater potential for migration but a lower capacity for adhesion, which may 
explain the lack of re-endothelialisation in vivo, when blood flow may obstruct cell adhesion 
(Dixit P et al 2001). 
Instead, the transmural pathway seems to enhance rapid endothelialisation, according to 
recent studies on materials with sufficient porosity. Pore size takes on importance in these 
studies, since the prosthesis must be sufficiently large to allow cell growth, but not too large 
to cause loss of intercellular adhesion (Mooney DJ et al 1996; Kim BS et al 1998; Wake MC et 
al 1996). Materials with differently sized pores inside and outside the conduit have even 
been experimented, in order to obtain an ecocompatible surface internally and a colonisable 
one externally (Mooney DJ et al 1996; Kim BS et al 1998; Wake MC et al 1996). 
Pore size also alters the haemocompatibility of biomaterials, as well as their compliance and 
degradation time. An optimal pore size for vascular engineering has been hypothesised, 
ranging from 30 to 50 microns. It appears that smaller pores would not allow growth of 
endothelial cells, and larger ones would cause excessive leakage of blood (Matsuda T et al 
1996). Pores in the walls of prosthetic materials can also avoid intimal hyperplasia. It has 
been hypothesised that a thrombus initially deposited on the walls of the prothesis later 
organises itself into muscle-like tissue, which then gives rise to intimal hyperplasia. The 
precocious growth of endothelial tissue would avoid thrombosis and thus the consequent 
cascade of events leading to intimal hyperplasia (Mooney DJ et al 1996; Kim BS et al 1998; 
Wake MC et al 1996). Increased pore size causes increased radial compliance of the material. 
Several studies have shown that vascular implants with fibers organised in a circular 
fashion do not cause dilation (Mooney DJ et al 1996; Kim BS et al 1998; Wake MC et al 1996). 
This is local, since cells undergo mechanical stress and are thus conditioned in their spatial 
orientation.  
‘‘Fall-out healing’’ leads to the formation of endothelial islands, with no connection with the 
formation of trans-anastomotic or transmural tissue. This is a late phenomenon, not of great 
importance in materials such as Dacron and e-PTFE grafts, and thus it does not play a 
central role in present-day prostheses (Zilla PD et al 2007), but it appears to be the 
mechanism for repairing small vascular lesions (Roberts NM et al 2005). However, recent 
studies show how this mechanism may be enhanced, by attracting EPC cells to participate 
(Avci-Adali MG et al 2010).  
3. Mechanical properties of biomaterials 
Before describing the mechanical properties of vascular replacements, we must digress to 
describe those of vessels. Arteries are mechanically anisotropic, i.e., their elasticity and 
resistance (maximum pressure tolerated before bursting) varies according to the direction 
along which they are measured. The capacity for distension of the arterial wall is generally 
called compliance (radial elasticity), or the difference in diameter obtained by varying 
www.intechopen.com
 New Developments in Tissue Engineering of Microvascular Prostheses 427 
pressures inside the artery itself (ΔD/DP) X 100). The two main structural proteins, collagen 
and elastin, confer several properties, enabling arteries to distend more at low pressure and 
become less elastic at high ones. Both properties are extremely important, since inadequate 
resistance may lead to rupture, and absence of elasticity may disturb flow, leading to 
thrombosis. In detail, the velocity of propagation (v) of pressure waves depends on the 
elasticity of vessel walls (E), their thickness (s) and diameter (D), and on the density (P) of 
blood, as described by the Moens-Korteweg equation, v= Es/ P D. When a section of artery 
and a replacement conduit have different radial elastic properties, two consequences may 
ensue. Discontinuity in the speed of propagation of pressure waves leads to turbulence in 
the area between the natural and artificial vessels which, in turn, leads to local overpressure, 
the cause of new aneurisms. Apart from the different degree of distension of arterial sections 
(original artery/prosthesis), this may put greater stress on sutures.  
Different compliance has been associated with intimal hyperplasia in an arterial 
replacement and the artery itself (Stewart SF et al 1992).  
Synthetic tissues are far less elastic than arteries, but absorbable materials which could be 
replaced by the normal vasal extracellular matrix are believed to avoid this problem. 
Resorption does very often trigger a response similar to that of a foreign body, which leads 
to the formation of scar tissue which may deprive the original construct of its elasticity (Zilla 
PD et al 2007).  
From the viewpoint of experimental models, elastic components are more or less the same in 
various species, in spite of changing sizes. Wolinsky and Glagov (1967) have shown that, 
whereas the total circumferential tension in the vascular wall of the aorta increases 26 times 
from mouse to pig, defined by Laplace's law as T=PR, tension per lamellar unit (elastic 
lamina) is similar, being about 1/ 3Nm-1 in various animal aortas, but unfortunately the 
above study does not compare peripheral vessels. Arterial elasticity causes a reduction in 
the pressure gradient generated during cardiac systole/distole (Wolinsky et al 1967; 
Shadwick RE 1999). In peripheral vessels, flow is continuous, thanks to the reservoir role 
played by the large vessels during cardiac systole. In humans, the ratio between flow 
gradient and mean flow falls from a value of 6 near the aortic arch to 2 distal to the femoral 
artery (Wolinsky et al 1967; Shadwick RE 1999). There is therefore a difference between the 
elasticity of vessels in relation to their size and position within the circulatory system which 
may influence the design of ideal replacements for them.  
According to the above, and in view of the complexity of the cardiocirculatory system and 
interactions with blood flow, some components are essential for neovessels if they are to 
guarantee sufficient resistance and compliance and, at the same time, avoid thrombosis and 
intimal hyperplasia (Mitchell SL et al 2003). At the present time, always in terms of totally 
absorbable products, there are many approaches involving heterologous tissues, synthetic 
polymers, biopolymers and totally engineered products (Isenberg BC et al 2006). Every 
experiment leads to different conclusions, and associations between materials to exploit 
desired properties while avoiding problems have also been proposed. For example, PGA is 
a generally stiff product and is frequently associated with other substances to achieve the 
necessary elasticity (Shinoka T et al 2008). 
4. Materials 
Many research groups all over the world have approached the problem of developing the 
ideal prosthesis in a variety of ways. As in all tissue engineering fields, research ranges round 
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the triad Scaffold/Cells/Growth Factor (Figure 2). Scaffolds are ideal biomaterials for 
conduits, and cells can be seeded and cultivated on them, after preconditioning with various 
growth factors. Very many materials have been used to make scaffolds, generally subdivided 
into four main categories: biological materials (allografts, xenografts, and derived products), 
natural proteins, and both permanent and absorbable synthetic polymers. 
 
 
Fig. 2. The traditional vascular tissue engineering approach. 
TEBV (Total Engineered Blood Vessels) 
Although this review covers biomaterials used as scaffolds in vascular tissue engineering, 
mention must be made of the methods for reconstructing small diameter vessels which do 
not use scaffolds. These mass-produced cell laminae are called TEBV (total engineered blood 
vessels). They have proven mechanical properties comparable with those of the saphenous 
vein until 8 months after implant. Their anatomic integration is excellent, showing the 
formation of vasa vasorum histologically in context and the presence of viable endothelium. 
Results have been so promising that the first studies for clinical application are under way 
(Mooney DJ et al 1996; Kim BS et al 1998; Wake MC et al 1996). However, TEBV can only be 
produced in the laboratory over a total period of about 3 months, which does not make them 
suitable for urgent procedures; they are also extremely expensive. Of the studies examined,  
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only 4 dealt with this method. One significant publication was a multi-centre cohort study 
illustrating the results of implanting TEBV in access routes in patients under dialysis. 
Although the cohort was composed of high-risk patients, primary patency of 76% was 
reported in the first 3 months (Mooney DJ et al 1996; Kim BS et al 1998; Wake MC et al 1996).  
Biological materials 
The first attempt at vascular replacement was made in 1908 with an allograft in dog, which 
earned its inventor the Nobel Prize for medicine (Carrel et al 1906). Since then, biological 
materials have been tested in various species (xeno- and allotransplants) and after various 
types of preparatory procedures (decellularisation to reduce the immune response, 
derivation of material for homogenisation, cryoconservation). These biomaterials are widely 
available and they are of course excellent substrates for cell adhesion. In addition, the 
processing method can retain all their advantageous mechanical properties (tensile strength, 
elasticity) (Schmidt CE et al 2000). As the main disadvantages are possible residual 
antigenicity and infection after implant (Chlupac JE et al 2009), techniques for their 
decellularisation and sterilisation have been refined. Articles on TEBV published in the last 5 
years (biological materials) mainly deal with materials already nautually present as tubular 
structures in the body (arteries, veins, urethers) and submitted to decellularisation. They are 
often studied as allo- or xenografts, and enriched with cells (Mooney DJ et al 1996; Kim BS et 
al 1998; Wake MC et al 1996), bFGF (Mooney DJ et al 1996; Kim BS et al 1998; Wake MC et al 
1996), heparin [42] and VEGF (Mooney DJ et al 1996; Kim BS et al 1998; Wake MC et al 1996) 
to improve patency in the long term. Of special interest for the physiopathology of tissue 
healing after implant is one study reporting trends after implants of decellularised porcine 
arteries in rat, concluding that the initial inflammation due to integration in tissues does not 
interfere with long-term modelling (Mooney DJ et al 1996; Kim BS et al 1998; Wake MC et al 
1996). One in vitro study examines the creation of a biotube produced by reaction to a foreign 
body (Mooney DJ et al 1996; Kim BS et al 1998; Wake MC et al 1996). Other studies examine 
the use of SIS (Small Intestinal Submucosa), already amply employed in clinical management 
of wounds. These studies show the good mechanical properties of this biomaterial (Hinds 
MT et al 2006), but also the poor long-term patency of conduits (Pavcnik D et al 2009).  
Permanent materials 
To replace large diameter vessels, synthetic materials are now routinely used in clinical 
practice, but synthetic polymers such as e-PTFE and Dacron have not given good results in 
small diameter vessels (<6 mm). In view of the enormous number of works on the subject, the 
problems of permanent synthetic polymers are clearly difficult to overcome. Many works 
report variable results in terms of long-term vasal patency, with consequent infection of the 
operation site (Mooney DJ et al 1996; Kim BS et al 1998; Wake MC et al 1996). During 
experimental studies, variable patency turned out to be considerable. These materials have 
been implanted in humans, but do not develop an endothelialised surface (Mooney DJ et al 
1996; Kim BS et al 1998; Wake MC et al 1996), thus causing platelet adhesion and the 
development of a fibrin layer which may lead to thrombosis. Later failure may also be due to 
thrombosis after stenotic occlusion of the vessel consequent upon the development of 
endothelial hyperplasia. Several methods have been applied in the past to reduce thrombosis 
after surgery (e.g., anti-thrombotic drugs in their surface or surface ligands (Kidane AG et al 
2004). Results were better, although clinically satisfactory criteria were not achieved. In the 
articles examined – that is, those published in the last 5 years – the main non-degradable 
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biomaterials were PTFE and polyurethanes. A total of 20 articles on PTFE were found, 16 of 
which described coating surfaces to avoid thrombosis or tissue hyperplasia. This approach is 
normally followed by endothelialisation of prostheses, and 8 articles described techniques for 
this (cell cultures). One review (Bordenave L et al 2005) illustrates how this procedure, in time, 
has moved from one-stage to two-stage techniques although, in spite of discouraging results, 
not much space was devoted to clinical practice, mainly because of its three most serious 
limitations: the impossibility of executing these techniques in emergencies; the need for prior 
withdrawal of cells; and the need for a GLP laboratory to treat human cells. 
The remaining approaches for surface coating do not involve cell cultures, and may be 
interesting as regards future applications of these products in combination with 
biodegradable materials. Fibrin has been proposed as a coating: results have been either 
discouraging (Mooney DJ et al 1996; Kim BS et al 1998; Wake MC et al 1996) or encouraging 
as regards anti-adhesive action in platelets and perlecan (Mooney DJ et al 1996; Kim BS et al 
1998; Wake MC et al 1996); one article reported an elastin-like recombining protein [84, 85, 
88]. Single peptides like RGD, cyclic RGD (Mooney DJ et al 1996; Kim BS et al 1998; Wake 
MC et al 1996) have also been proposed, but only in vitro studies are available (Walpoth BH 
et al 2007; Lord MS et al 2009; Jordan SW et al 2007; Tang C et al 2009; Larsen CC et al 2007).  
Polyurethane materials 
Polyurethanes are polymers composed of chains of organic units joined by urethane bonds, 
formed by polymerisation, generally with reagents like monomers containing al least 2 
hydroxyl groups (diol), dioisokyanate, and a chain extender. They react to form linear 
copolymers, segments consisting of alternating stiff and soft segments. The soft segments 
are derived from polyols such as polyester and the hard ones from isocyanate and chain 
extenders (e.g., lactic acid/ethylenglycol) (Atala et al 2008). These polymers are 
biocompatible and highly versatile, since their tensile strength and radial compliance vary 
according to segment composition (Tiwari et al 2003), stiff segments being responsble for 
tensile strength and soft segments for elasticity (Kannan et al 2005). Originally produced as 
permanent biomaterials, they do deteriorate in vivo, due to oxidation and enzymatic and 
cell-mediated degradation, with the result that their biostability is under revision (Mooney 
DJ et al 1996; Kim BS et al 1998; Wake MC et al 1996). Oxidation of PU is initiated by 
oxidase, free radicals and enzymes. The phenomenon of environmental stress cracking is 
also due to oxidation, a process in which the surface of the biomaterial is coated with 
proteins which recall adhesion by macrophages, which release oxidising factors (Stokes KR 
et al 1995). These discoveries were made in the early 1990s and led to the classification of PU 
as a new category of absorbable materials (Santerre JP et al 2005). 
The differing composition of PU segments may lead to products with various degrees of 
biostability. As regards dioisokyanates/, the aromatic forms are more stable than the 
aliphatic ones (Fromstein JDW et al 2006; Mooney DJ et al 1996; Kim BS et al 1998; Wake MC 
et al 1996), although the former were abandoned after it was noted that they release toxic 
substances with carcinogenic effects (hepatocarcinoma) in laboratory animals (Gunatillake 
et al 2003). PU have been combined with highly crystalline segments such as polycarbonates 
and silicon oligomers to inrease their stability (Atala et al 2008). Degradable polyesters such 
as PLA, PGA and PCL have also been associated as weak segments. Carbonate PU have 
shown good resistance to hydrolysis and oxidative stress (Salacinski HJ et al 2002). In one in 
vivo study, such prostheses were implanted in the aorto-iliac segment of dog, where they 
remained viable for more than 36 months (Mooney DJ et al 1996; Kim BS et al 1998; Wake 
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MC et al 1996). PU have excellent radial compliance, but are structurally weaker than the 
others, being more rapidly degraded due to their typical ester bonds (Guan J et al 2002). As 
well as biodegradability, PU have shown good biocompatibility in in vivo tissue studies 
(Mooney DJ et al 1996; Kim BS et al 1998; Wake MC et al 1996). 
The development of small diameter vascular prostheses in the last 5 years revealed a total of 
22 articles on polyurethanes, 14 in vitro, 4 on production of material and and its medical 
properties, and only 4 in vivo. The cellular compatibility of several PU (associated with 
other substances) has also been studied according to method of preparation, e.g., the use of 
porous structures. 
Electrospinning has been applied to other materials in the field of vascular engineering 
(Mooney DJ et al 1996; Kim BS et al 1998; Wake MC et al 1996), and produces small diameter 
fibers with good tensile strength on the final material. However, this method is difficult to 
apply when large pores are required. In theory, the immersion-leaching technique (Pan S et al 
2005) should not create interconnected pores and thus not be favourable to cell growth, 
whereas phase inversion (Mooney DJ et al 1996; Kim BS et al 1998; Wake MC et al 1996) may 
fail in both interconnections and pore size. One in vivo study examined the PU produced by 
induction of thermal phase separation, but the resulting biomaterial had poor tensile strength 
and the overall results in terms of implant viability, presence of aneurisms and vessel 
functionality were mediocre (Mooney DJ et al 1996; Kim BS et al 1998; Wake MC et al 1996).  
As regards chemical composition, PU has been combined with silk fibroin, showing better 
histocompatiblity of pure PU after implant in rat muscular tissue (Wang W et al 2010). Many 
experiments have also been made on the mixed-composition PU PDMS 
(polydimethylsiloxane), a silicon-based polymer (Mooney DJ et al 1996; Kim BS et al 1998; 
Wake MC et al 1996). In this case, PDMS not only increased biostability but also increased 
haemocompatibility and immunocompatibility (Mooney DJ et al 1996; Kim BS et al 1998; 
Wake MC et al 1996). In in vivo studies (Mooney DJ et al 1996; Kim BS et al 1998; Wake MC 
et al 1996) show encouraging long-term viability: in one (Khorasani MT et al 2006), a 
PEUU/PDMS polymer was created with the spray phase inversion technique in a tubular 
form with two-phase porosity: a highly porous internal wall (mean interfibrillar distance 40 
microns) and an only slightly porous outer one (mean interfibrillar distance 30 microns). It 
showed good re-endothelialisation 24 months after implant, with remodelling of the vessel 
parallel with digestion of the material, without aneurismatic dilation or calcification. 
However, the sample size was very small, and the prostheses showed uniform dilation over 
time.Another in vivo study in this series used poly(ester urethane)urea (PEUU) combined 
with a thrombogenic polymer not similar to a phospholipid, poly(2-methacryloyloxyethyl 
phosphorylcholine-co-methacryloyloxyethyl butylurethane) (PMBU), to create a fibrillar 
scaffold by electrospinning, with good tensile strength and compliance. In addition, the 
association with PMBU made the PU less prone to platelet deposition and hypertrophy of 
muscle cells. The in vivo patency of 1.3-mm conduits implanted in rat aorta after 8 weeks 
varied from 40% for pure PU to 67% for PU PMBU (Hong Y et al 2009). 
Bioresorbable materials 
In the last five years, most research groups have concentrated on testing absorbable/ 
biomaterials to achieve the ideal vascular conduit. As already mentioned, the materials in 
question may be synthetic or biopolymers already constituting the extracellular matrix. 
The most common absorbable biomaterials are polyesters. This category contains poly(α-
hydroxylester poly(L-lactic acid) (PLLA), poly(-glycolic acid) (PGA), polylactone 
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polyorthoesters (POE) and polycarbonates. When these materials are implanted in living 
tissues, their polymeric structure is subject to hydrolysis and the resulting products, such as 
lactic and glycolic acids, are metabolized. Their safety and biocompatibility are now 
established (Mooney DJ et al 1996; Kim BS et al 1998; Wake MC et al 1996). 
It is generally difficult to examine the use of these biomaterials separately, as they are all 
linked in the field of vascular tissue engineering. The first to be examined was polyglcolic 
acid, an asborbable polyester, which has shown good biocompatibility and is chosen for 
many applications (Mooney DJ et al 1996; Kim BS et al 1998; Wake MC et al 1996).  
Polyglycolic acid was the first biodegradable polymer to be used in vascular engineering 
[84, 85, 88]. It was tested in combination with cultivated bovine muscle cells and then 
preconditioned in a pulsatile flow bioreactor. After 8 weeks, this construct revealed collagen 
and had good mechanical properties. Its tensile strength is comparable to that of a vein. 
However, it also begins to lose its mechanical resistance within 4 weeks of implant and is 
completely degraded at 6 months. Degradation speed can be controlled by associating it 
with other polymers such as poly-L-lactic acid (PLLA), polyhydroxyalkanoate (PHA), 
polycaprolactonecopolylactic acid, and polyethylene glycol (Mooney DJ et al 1996; Kim BS 
et al 1998; Wake MC et al 1996). 
However, the mechanical resistance of these products does not reach the desired levels – an 
anticipated outcome, as PGA was originally in the form of a non-woven fabric, and thus 
does not have measurable tensile strength (Sodian R et al 2000). Most studies have therefore 
concentrated on preconditioning methods to increase resistance, e.g., use of pulsatile flow 
bireactors, alternative techniques of cell culture, and administration of various growth 
factors (Niklason LE et al 1997). 
Another substantial problem with PGA is its stiffness, which does not confer the elastic 
properties typical of arterial tissues (Sodian R et al 2000). In this case too, the use of 
copolymers has improved results. A fibrillar scaffold based on polyglycolic or polylactic 
acid coated with a 50:50 L-lactate or L-caprolactone (PCLA/PGA or PCLA/PLA) copolymer 
has been specifically tested for vascular repair, resulting in compliance closer to that of the 
original vessel with better surgical handling (Watanabe M et al 2001).  
One study showed how PGA-based matrices have greater cellularity and production of 
proteins of extracellular matrices based on PHAV and P4HB. The authors explained this 
phenomenon as due to the higher porosity of PGA (> 90%), yielding a contact surface 
greater than that of cells (Sodian R et al 2000). 
To support the remodeling process in vivo, a biomaterial that functions only as a temporary 
absorbable guide, similar to an in vivo “Artery-Bioregeneration Assist Tube” (ABAT), which 
can promote the sequential and complete regeneration of vascular structures at the 
implantation site, entirely made of Hyaluronic Acid was used in different in vivo 
experimental model (Lepidi et al 2006; Pandis L et al 2010; Zavan B et al). 
5. Conclusion 
Critical reading of researches in the field of microvascular tissue engineering gave the general 
impression of progress in the search for an ideal replacement for small diameter vessels.  
Most studies indicate the use of absorbable biomaterials, in view of their good integration, 
with the hope of developing autogenous vessels to replace prostheses. However, not one of 
these products has yet been approved for clinical experimentation, unlike TEBV and 
products of biological origin. Degradability is one of the characteristics which tend to  
www.intechopen.com
 New Developments in Tissue Engineering of Microvascular Prostheses 433 
 
Fig. 3. Regenerative medicine is based on “intelligent” biomaterials able. 
dissuade surgeons at the crucial moment of implant. In addition, other variants have been 
added, making the subject a spiny one. For example, on one hand, the porosity or fibrillar 
form of these materials not only alters their biostability but also their mechanical 
characteristics, which are today believed to be essential for implant success. On the other 
hand, the variability of clinical applications, which may differentiate the desired 
characteristics of each type of material, requires reflection. 
There are many gaps in the examined articles. The first problem, already examined by many 
authors, is variability in animal models, which hinders direct comparison of results. 
Homogeneous studies on mechanical studies are also lacking, since so many of them focus 
on tensile strength, and neglect compliance, which is an essential feature of vessels.  
An effective model of an artificial vessel is very far from being achieved, and its 
development must take into account the context in which it could be applied. Experimental 
models have already been super-ceded, if we think that the application of a bio-absorbable 
prosthesis means that cells must be able to reconstruct a new artery and that, in clinical 
practice, this must be achieved in already damaged arteries.  
In elective vascular surgery (e.g., arterial insufficiency in the lower limbs), cellularised 
replacements are possible, tailored to suit single patients according to their tissue biopsy. 
However, the procedures are time-consuming and very expensive, requiring dedicated 
laboratories able to guarantee sterility and suitability for in vivo re-implantation of cell 
cultures.  
As regards urgent procedures, such as revascularisation of all types, the cell culture step 
should be avoided. The ideal choice would be ready-to-use materials (Figure 3). 
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